Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary

Achieved full-year profitability and positive cash flow within nine months of the VYKAT XR launch, driven by strong adoption in the PWS market. Captured approximately 12.5% of the addressable U.S. market by year-end, with 859 patients on active treatment and 1,250 total start forms received. Attributed durable growth to high prescriber engagement, with 630 unique prescribers and significant utilization across both pediatric and adult (ages 27-45) populations. Maintained a real-world safety profile c ...